Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome

Citations Over TimeTop 10% of 2017 papers

Abstract

Somatic mutations in spliceosome genes are detectable in ∼50% of patients with myelodysplastic syndromes (MDS). We hypothesize that cells harbouring spliceosome gene mutations have increased sensitivity to pharmacological perturbation of the spliceosome. We focus on mutant U2AF1 and utilize sudemycin compounds that modulate pre-mRNA splicing. We find that haematopoietic cells expressing mutant U2AF1(S34F), including primary patient cells, have an increased sensitivity to in vitro sudemycin treatment relative to controls. In vivo sudemycin treatment of U2AF1(S34F) transgenic mice alters splicing and reverts haematopoietic progenitor cell expansion induced by mutant U2AF1 expression. The splicing effects of sudemycin and U2AF1(S34F) can be cumulative in cells exposed to both perturbations-drug and mutation-compared with cells exposed to either alone. These cumulative effects may result in downstream phenotypic consequences in sudemycin-treated mutant cells. Taken together, these data suggest a potential for treating haematological cancers harbouring U2AF1 mutations with pre-mRNA splicing modulators like sudemycins.

Related Papers

• → Modulating splicing with small molecular inhibitors of the spliceosome(2016)173 cited
• → Transient interaction of BBP/ScSF1 and Mud2 with the splicing machinery affects the kinetics of spliceosome assembly(1999)96 cited
• → A Novel Splicing Factor, Yju2, Is Associated with NTC and Acts after Prp2 in Promoting the First Catalytic Reaction of Pre-mRNA Splicing(2007)84 cited
• → A High-Throughput Splicing Assay Identifies New Classes of Inhibitors of Human and Yeast Spliceosomes(2013)37 cited
• → Human step II splicing factor hSlu7 functions in restructuring the spliceosome between the catalytic steps of splicing(1999)55 cited